Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 39 analyst ratings
Buy
Strong Buy 26%
Buy 36%
Hold 36%
Sell 3%
Strong Sell 0%

Bulls say

Edwards Lifesciences is projected to achieve a revenue of $5.83 billion by 2025, reflecting a 9.2% year-over-year growth, driven largely by a $4.27 billion forecast in TAVR (transcatheter aortic valve replacement) sales, which are expected to grow 6.2% operationally. The company has experienced strong growth in its TMTT (transcatheter mitral and tricuspid therapies) segment, boasting an impressive year-over-year increase of 85% in Q4, further supported by positive sales performance in other key regions, including a notable 9.3% underlying growth in TAVR sales for Q4. Additionally, the firm anticipates the global TMTT market will expand to $5 billion in the future, indicating a promising outlook for continued market penetration and product demand.

Bears say

Edwards Lifesciences is facing a challenging outlook, with management anticipating Q1 2025 growth rates for both the total company and TAVR to fall below their respective full-year guidance ranges, primarily due to one less selling day in the quarter. Additionally, potential revenue growth headwinds are exacerbated by macro factors such as hospital staffing shortages and inflation, as well as heightened competition and challenges in market penetration for newer technologies. The adverse impact of foreign exchange fluctuations is expected to further hinder sales by approximately $130 million, contributing to overall negative projections for the company's performance.

Edwards Lifesciences (EW) has been analyzed by 39 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 39 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.